ZED-1227 is a specific and orally active transglutaminase 2 (TG2) inhibitor, with an IC 50 of 45 nM. ZED-1227 can block inflammation-induced TG2 expression and activity. ZED-1227 can be used for the research of celiac disease (CeD) In Vitro ZED-1227 (0.1 μΜ-1 μΜ; 24 hours) has no effect on metabolic activity and proliferation in Huh7 cells and CaCo2 cells, that suggests ZED-1227 has no cytotoxic activity. ZED-1227 (0.002-0.2 mg/mL; 30 minutes) inhibits TG2 in the small intestinal mucosa in vitro. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo ZED-1227 reduces the activity of intestinal TG2 induced by Polyinosinic:Polycytidylic acid (40 mg/kg) to normal control levels and subdues intestinal inflammation in mice . ZED-1227 (5 mg/kg; i.g.) is able to inhibit TG2 in the small intestinal mucosa. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: BALB/c miceDosage: 5 mg/kg Administration: Oral gavage Result: Inhibited TG2 in vivo in the small intestinal mucosa. Form:Solid IC50& Target:IC50: 45 nM (TG2)